Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"

Research involving non-interventional humans. Selection and inclusion of patients by CHSD investigators. Collection of clinical data by investigators and CHSD URC staff.

Biochemical and hematological measurements by the CHSD medical biology laboratory for "care" samples Pseudonymization of 4 mL "research" samples by the URC then fractionation of the samples by 1 mL, and storage at -80°C within the medical biology laboratory of the CHSD.

Transport of samples at -80°C to team 1 of Dr Baudin-Creuza (Créteil). Preparation of genomic DNA from a 1 mL fraction then α and β globin genotyping by Dr Pissard.

Measurement of the AHSP concentration from the other fractions. Comparison of the AHSP concentration according to the group of subjects, and with the different parameters, then correlation analysis

Inclusion criteria

Inclusion criteria

for Sickle Cell Patients

• Adults: > 15 years and 6 months
• Pediatrics: ≥ 3 years and ≤ 15 years and 6 months
• Known SS or Sβ0 phenotypes

Inclusion criteria

for Control Patients.

1 -Adults: > 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration

-Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder

4-Blood sample planned as part of medical care

Exclusion criteria

• Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients)
• Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients)
• Transfusion less than 3 months ago
• Chronic active viral disease: hepatitis B, C, HIV
• Current infections or known inflammatory pathologies
• Known hyper or hypothyroidism or subject treated with levothyroxine
• Active tumor pathology or remission for less than 5 years
• Oral corticosteroid therapy in progress
• Participation in interventional biomedical research
• Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor.
• Non-affiliation to a social security system